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Abstract
The Chocolate BAR study is a prospective multicenter post-market registry designed to evaluate
the safety and performance of the Chocolate percutaneous transluminal angioplasty balloon cathe-
ter in a broad population with symptomatic peripheral arterial disease. The primary endpoint is
acute procedural success (defined as 30% residual stenosis without flow-limiting dissection); sec-
ondary long-term outcomes include freedom from target lesion revascularization (TLR), major
unplanned amputation, survival, and patency. A total of 262 patients (290 femoropopliteal lesions)
were enrolled at 30 US centers between 2012 and 2014. The primary endpoint of procedure suc-
cess was achieved in 85.1% of cases, and freedom from stenting occurred in 93.1%. Bail out
stenting by independent adjudication occurred in 1.6% of cases and there were no flow limiting
dissections. There was mean improvement of 2.1 Rutherford classes (61.5) at 12-months, with
78.5% freedom from TLR, 97.2% freedom from major amputation, and 93.3% freedom from all-
cause mortality. Core Lab adjudicated patency was 64.1% at 12 months. Use of the Chocolate bal-
loon in an “all-comers” population achieved excellent procedural outcomes with low dissection
rates and bailout stent use.
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1 | INTRODUCTION
Peripheral arterial disease (PAD) carries a significant global health
burden, and can limit functional capacity and quality of life [1]. Per-
cutaneous transluminal angioplasty (PTA) for PAD is often associated
with suboptimal outcomes due to complications following balloon
inflation related to vessel trauma and flow limiting dissections that
may require bailout stenting. Novel strategies and techniques to
enhance both acute and longer-term outcomes with PTA are
needed.
The Chocolate PTA balloon catheter (TriReme Medical LLC, Pleas-
anton, CA) is a standard balloon constrained by a nitinol scaffold that
sub-segments the balloon when inflated, creating valleys and grooves
on the balloon surface that increase the contact surface area of the
Chocolate balloon catheter (Figure 1). The intent of this balloon design
is to disperse the force associated with angioplasty along this increased
contact surface resulting in a controlled and differential dilatation
approach to minimize overall vessel trauma. The Chocolate BAR post-
market registry is intended to evaluate the safety and performance of
the Chocolate PTA balloon catheter in a broad population.
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2 | MATERIALS AND METHODS
This is a prospective multicenter post-approval study evaluating the
use of the Chocolate PTA balloon in patients with femoropopliteal
atherosclerotic disease at 30 US clinical centers. Patients with femoro-
popliteal disease were eligible for enrollment after successfully crossing
the target lesions, if they had angiographic evidence of distal run-off
immediately prior to the use of Chocolate Balloon and at least one pat-
ent tibial vessel. Patients were excluded if primary stenting was
planned, if a flow-limiting dissection was present prior to Chocolate
Balloon use, if life expectancy was <12 months or the patient was
enrolled in another investigational study. The Institutional review board
or ethics committee approved the trial and all patients provided
informed consent. The cohort is defined by treatment of femoropopli-
teal vessel disease including the superficial femoral artery (SFA) and
P1/P2 segments of the popliteal artery.
The Chocolate PTA Balloon is available in diameters of 2.0–
6.0 mm and lengths of 20–120 mm. The Chocolate Balloon was sized
1:1 with the target vessel diameter. Multiple inflations and sizing up
with a larger Chocolate Balloon in cases with residual stenosis were
permitted with a recommendation to inflate the Chocolate balloon to
half nominal for 30 sec followed by a slow inflation to nominal for an
additional 90 sec. Prolonged balloon inflation with Chocolate or con-
ventional PTA for at least 5 min was recommended for suboptimal
results, and if no improvement, bail-out stenting was permitted.
Clinical evaluation and outcomes are reported up to 12 months.
Clinical assessments were performed at 1, 6, and 12 months and
included Ankle Brachial Index (ABI), Rutherford Assessments, and
Duplex Ultrasound at each visit.
The primary endpoint was procedure success defined as a target
lesion residual stenosis of 30% stenosis without a flow-limiting dis-
section after Chocolate balloon adjudicated by independent angio-
graphic core laboratory analysis. Secondary study endpoints included
the rate of acute bailout stenting for suboptimal results; improvement
in Rutherford classification or ankle/toe brachial index from baseline;
freedom from target lesion revascularization (TLR) at 1, 6, and 12
months; major amputation, defined as unplanned amputation at or
above the ankle at 12 months; 6- and 12-month patency, defined as
freedom from restenosis at the target lesion (diameter stenosis >50%
based on duplex ultrasound and peak systolic velocity (PSV) ratio <2.5)
without the need of TLR.
An independent clinical event committee (Yale Cardiovascular
Research Center, Yale University School of Medicine, New Haven, CT)
adjudicated all clinical events with causal relationship to the Chocolate
Balloon. An independent angiographic core laboratory (Yale Cardiovas-
cular Research Center, Yale University School of Medicine, New
Haven, CT) reviewed and analyzed all angiograms using validated
Quantitative Vascular Angiography (QVA) software (MEDIS, Leiden,
The Netherlands). Dissections were classified according to the NHLBI
Dissection Classification System (1985), which defines flow-limiting dis-
sections as Types E and F. An independent Duplex ultrasound core lab-
oratory (VasCor, Massachusetts General Hospital) reviewed all duplex
ultrasounds using standard methodology. Severe calcification was
defined as calcific radiopacities noted on both sides of the arterial wall
by angiography prior to contrast injection and extending more than
1 cm of length.
3 | RESULTS
A total of 262 patients were enrolled over 30 months from June
2012 to December 2014. The 262 patients had 290 femoropopliteal
atherosclerotic lesions enrolled at 30 sites in the United States.
There was adequate data on 263 lesions for lesion analysis. At
12 months 203 (77.5%) patients completed follow-up or met the
study endpoint and 12.6% withdrew consent. Another 9.9% were
lost to follow-up.
Baseline characteristics are summarized in Table 1. Initial presenta-
tion with critical limb ischemia (CLI) occurred in 32.1%. The Chocolate
PTA balloon was effectively delivered to and inflated at the intended
lesion in 100% of cases (Table 2).
FIGURE 1 The Chocolate balloon. The nitinol scaffold sub-
segments the balloon when inflated
TABLE 1 Baseline patient characteristics
n5262
Age, years mean (6SD) 69.7 610
Male gender 160 (61.1%)
Diabetes mellitus 132 (50.4%)
Hypertension requiring medications 241 (92.0%)
Hyperlipidemia requiring medications 222 (84.7%)
Obesity 42 (16.0%)
Prior stroke 24 (9.2%)
Prior MI 36 (13.7%)
History of CAD 151 (57.3%)
Current smoker 77 (29.4%)
Past smoker 151 (57.6%)
Baseline mean Rutherford Class, mean (SD) 3.3 61
0—Asymptomatic 0%
1—Mild claudication 1 (0.4%)
2—Moderate claudication 55 (21.0%)
3—Severe claudication 122 (46.6%)
4—Ischemic rest pain 34 (13.0%)
5—Minor tissue loss 50 (19.1%)
6—Major tissue loss 0%
MI, myocardial infarction; CAD, coronary artery disease.
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The primary endpoint (procedure success: 30% DS without a
flow-limiting dissection) was achieved in 85.1% of patients with the
Chocolate balloon (Table 2). Bail out stenting for a residual stenosis of
>30% was used in 1.6% (n54). Dissections were identified in 22.5%;
2% grade A, 9.5% grade B, 10.7% grade C, 0.4% grade D; none were
flow-limiting (grades E or F) by angiographic Core Laboratory. The 12-
month patency (PSV ratio<2.5 by duplex ultrasound and no TLR) was
64.1% by core lab and 68.3% by site report. At 12 months, freedom
from TLR was 78.5% (Figure 2), freedom from major unplanned ampu-
tation 96%, and freedom from all-cause mortality 94%. Twelve-month
clinical improvement was 89.3% with a 2.1 61.5 average decrease in
Rutherford score.
Amongst the subgroup of patients with site-determined severe cal-
cification (n577, 29.4%), freedom from TLR was 87% at 12-months.
Freedom from TLR, absence of occlusion and PSV<2.5 in the severely
calcified group was 48.5%, with a 12-month primary patency of 72.7%,
and freedom from amputation was 96%.
4 | DISCUSSION
The Chocolate Balloon Registry confirms, in a post market study, that
the novel design of the Chocolate balloon is associated with excellent
acute procedural results without flow-limiting dissections. This strategy
affords the benefit of minimizing the use of bail out stenting and pro-
vides an alternative to primary stenting with excellent 12-month pri-
mary patency rates and low rates of TLR.
Endovascular techniques and outcomes with standard PTA and
stenting have improved over time and have become first-line revascu-
larization strategies for patients with symptomatic PAD. However with
stenting, restenosis in the superficial femoral and/or popliteal artery
continue to occur in 20%–50% of patients at 12 months [2–4].
Several biomechanical forces acting on the SFA during movement
are inherent limitations that metallic stents cannot overcome. With leg
movement, flexion points as well as muscular forces lead to ongoing
compression, torsion, elongation and flexion forces that contribute
to stent fracture, restenosis, and possibly in-stent thrombosis [5–7].
TABLE 2 Baseline and procedural lesion characteristics
Lesion characteristics N5263
Lesion length (mm) 83.5659.9 (n5250)
Total occlusions 60/260 (23.1%)
Lesion calcification
None/Mild 93/254 (36.6%)
Moderate 110/254 (43.3%)
Severe 51/254 (20.1%)
% diameter stenosis, pre-treatment
(mean6 SD)
73.5617.3
% diameter stenosis, post-treatment
(mean6 SD)
22.068.4
Minimal lumen diameter (mm),
pre-treatment (mean6 SD)
1.360.9
Minimal lumen diameter (mm),
post-treatment (mean6 SD)
4.160.7
Acute luminal gain (mm) (mean6 SD) 2.860.7
Achieved <530% DS without flow-
limiting dissection
85.1%
FIGURE 2 Kaplan–Meier—freedom from TLR, major unplanned amputation, all-cause mortality. [Color figure can be viewed at wileyonline-
library.com]
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Self-expanding memory alloy stents, such as nitinol, intended to reduce
stent fracture have not eliminated the problem with reported fracture
rates at 1 year ranging from 2% to 18% in longer stented segments
[8–11] and as high as 27% with overlapping stents [12]. An additional
major challenge with stenting is diffuse in-stent restenosis or in-stent
occlusion, which can be a very difficult problem to treat [2,13] with
recurrent restenosis rates in excess of 70% at 1–2 years, though recent
results have suggested improved outcomes with peripheral drug-
eluting stents and DCB [14–16].
Given the limitations of stent implantation, a primary revasculariza-
tion approach with the Chocolate balloon offers a viable therapeutic
alternative to primary stenting that does not limit future treatment
options; a major consideration given the chronic and progressive nature
of PAD. The Chocolate BAR registry represents an “all comers” patient
population, allowing high-risk Rutherford 5 and 6 patients, one-third
presenting with CLI, as well as patients with severely calcified lesions
and chronic total occlusions. The acute and long-term outcomes of the
Chocolate balloon for femoropopliteal intervention are favorable com-
pared to other non-sent approach in other high risk cohorts, with
greater freedom from amputation and similar revascularization rates
with the Chocolate balloon. For example, the all comers XLPAD Regis-
try treated with non-stent interventions (42.6% atherectomy) reported
a 15% repeat revascularization and 9.2% amputation rate [17]. Com-
pared to standard PTA series, where reported primary patency are 52%
with similar clinically driven TVR rates, an important advantage of the
Chocolate Balloon is the absence of flow limiting dissections compared
to those reported with standard PTA (60%–70%) [18]. Sirignano et al.
[19] evaluated the Chocolate Balloon in 84 consecutive patients with
Rutherford 3 claudication and femoropopliteal disease, in a single cen-
ter study. After Chocolate Balloon angioplasty, drug-coated balloon
angioplasty was utilized. At a mean follow-up of 12.3 months, freedom
from TLR was 97.6% and Rutherford score improvement of 2 or more
were seen in 85.4%. The extent of calcification did not appear to affect
outcomes in this small study. In the recent Levant 2 trial, standard bal-
loon angioplasty demonstrated a 1-year patency of 52.6%, clinically
driven TVR of 18% but SFA dissection rates were 72.3% [20]. In com-
parison, the Chocolate balloon demonstrated a superior 12-month pri-
mary patency (64.1%) with dissection rates of only 22.5% and no flow
limiting dissections.
The paclitaxel-coated Chocolate balloon (Chocolate Touch)
received European CE Mark approval in 2015 and is currently being
evaluated for safety and efficacy in the ongoing US IDE ENDURE trial.
Preliminary data support the benefit of the combination of the low dis-
section and drug delivery single device option [21].
This study has limitations as a non-randomized “all-comers” regis-
try with a broad range of indications and lesion locations. A third of the
study population had CLI. We cannot report this cohort to represent all
populations with PAD, however, as patients without one patent tibial
artery were excluded. Furthermore, even though long lesions were
treated, the mean lesion length was 83.5659.9 mm. The operator may
have had an implicit bias against treating longer lesions with the Choc-
olate balloon alone. This study, however, is more representative and
relevant to everyday clinical practice including patients with longer
lesions, chronic occlusions, CLI, and heavy calcification. Also there was
attrition, with loss to follow-up of 9.9% and study withdrawal of
12.6%, with 77.5% completing follow-up or meeting the study end-
point at 12 months.
5 | CONCLUSION
The Chocolate BAR Registry confirms that the “low trauma” mecha-
nism of the Chocolate balloon achieved excellent procedural outcomes,
low rates of dissection, and minimal bail out stent use with high long-
term patency and low rates of revascularization despite the high com-
plexity of the population. These data support the use of the Chocolate
balloon for use in femoropopliteal lesions.
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